Video Experimental Relacionado
Updated: Jun 5, 2025
09:37
Optimized Negative Staining: a High-throughput Protocol for Examining Small and Asymmetric Protein Structure by Electron Microscopy
Published on: August 15, 2014
43.5K
Estructura de la apolipoproteína B100 unida al receptor de lipoproteína de baja densidad
Mart Reimund1, Altaira D Dearborn2, Giorgio Graziano1
1Lipoprotein Metabolism Laboratory, Translational Vascular Medicine Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
Nature
|December 11, 2024
Resumen
Los conocimientos estructurales sobre las interacciones de la apolipoproteína B100 (apoB100) y el receptor de LDL (LDLR) revelan cómo las mutaciones causan hipercolesterolemia familiar, ofreciendo objetivos para las terapias de enfermedades cardiovasculares.
Área de la Ciencia:
- Biología estructural
- La bioquímica
- Investigación cardiovascular
Sus antecedentes:
- La apolipoproteína B100 (apoB100) es crucial para la estructura de las lipoproteínas de baja densidad (LDL) y la unión de las LDLR.
- Las mutaciones en apoB100 o LDLR conducen a hipercolesterolemia familiar, aumentando el riesgo de enfermedad cardiovascular.
- La base estructural de la interacción apoB100-LDLR sigue siendo en gran medida desconocida.
Objetivo del estudio:
- Para dilucidar las estructuras de alta resolución de apoB100 en el LDL unido al LDLR.
- Comprender los mecanismos moleculares subyacentes a las interacciones LDL-LDLR y su papel en la hipercolesterolemia familiar.
Principales métodos:
- Se empleó la criomicroscopia electrónica (Cryo-EM) para determinar las estructuras complejas.
- Se utilizó el refinamiento local para lograr una alta resolución de las interfaces de interacción.
- Análisis de los sitios de mutación asociados con la hipercolesterolemia familiar.
Principales resultados:
- Se resolvieron las estructuras detalladas de dos interfaces de enlace clave apoB100-LDLR.
- Una interfaz involucra módulos de unión de ligando LDLR y el cinturón beta de apoB100.
- La segunda interfaz conecta el dominio beta-hélice de LDLR con el N-terminal de apoB100.
- Identificó cómo estas interfaces median la formación de dímeros de LDL y los cambios conformacionales de LDLR.
- Las mutaciones asociadas a la enfermedad en apoB100 y LDLR están localizadas en la interfaz LDL-LDLR.
Conclusiones:
- Proporciona detalles estructurales sin precedentes del complejo apoB100-LDLR.
- Explica la base estructural para la unión de LDL y la posible disfunción de LDLR en la hipercolesterolemia familiar.
- Destaca la interfaz LDL-LDLR como un sitio crítico para comprender y potencialmente tratar la hipercolesterolemia.
Más Videos Relacionados
Videos de Conceptos Relacionados
01:39Receptor-mediated Endocytosis
104.0K
Overview
104.0K
01:29Drug Distribution: Plasma Protein Binding
4.9K
Drugs predominantly attach to plasma proteins, with only a small percentage remaining unbound. The unbound portion can be calculated as one minus the bound fraction. Acidic drugs form large, inactive complexes by reversibly binding to plasma albumin, which prevents them from diffusing across biological barriers. These drug-protein complexes act as reservoirs for the drugs. As the concentration of unbound drugs decreases, these complexes quickly dissociate to release the free drug, maintaining...
4.9K
01:30Drug Binding to Blood Components
110
When drugs enter systemic circulation, they interact with various components of the blood, including proteins such as human serum albumin (HSA), α1-acid glycoprotein (AAG), lipoproteins, globulins, and red blood cells (RBCs).
HSA is the most abundant plasma protein and is vital in drug binding. It contains distinct drug-binding sites, with different drugs exhibiting affinity for specific sites. There are three main drug-binding domains for HSA: sites I, II, and III. These domains are...
HSA is the most abundant plasma protein and is vital in drug binding. It contains distinct drug-binding sites, with different drugs exhibiting affinity for specific sites. There are three main drug-binding domains for HSA: sites I, II, and III. These domains are...
110
01:45Regulation of Nuclear Protein Sorting
2.4K
Nuclear protein sorting regulates nucleus composition and gene expression, crucial for determining the fate of a eukaryotic cell. Hence, the entry and exit of molecules across the nuclear envelope is a tightly controlled process. Nuclear protein sorting can be inhibited by one of the following ways: 1) masking cargo signal sequences, 2) modifying the nuclear receptor's affinity for cargo, 3) controlling the nuclear pore size, 4) retaining the cargo during its transit to the cytosol or the...
2.4K
00:59COP Coated Vesicles
7.7K
Membrane-enclosed structures called vesicles transport proteins and lipids across the cell. The vesicles derive their cargo from the plasma membrane, Golgi, ER, or endosome. Coated vesicles are spherical, protein-coated carriers with a 50–100 nm diameter that mediate bidirectional transport between the ER and the Golgi. The distribution of proteins between the ER and Golgi complex is dynamic and is maintained by different coated vesicles. Their formation is driven by the assembly of...
7.7K
01:12Clathrin Coated Vesicles
6.8K
Clathrin-coated vesicles use endocytosis to transport receptors and lysosomal hydrolases from the Golgi to the lysosome in the late secretory pathway. Clathrin-mediated endocytosis was the first described endocytic process, and Clathrin-coated vesicles remain one of the most well-studied transport vesicles. The molecular machinery that generates clathrin-coated vesicles comprises over 50 proteins that precisely coordinate vesicle formation. Cell surface receptors concentrated in indented sites...
6.8K